Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed

(Infanrix®)

Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed

Drug updated on 3/28/2024

Dosage FormInjection (intramuscular: 0.5 mL)
Drug ClassVaccines
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the seventh birthday).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Infanrix) is used for active immunization against diphtheria, tetanus, and pertussis in infants and children aged 6 weeks through 6 years.
  • A systematic review/meta-analysis of ten studies was conducted to determine the effect of Tdap immunization during pregnancy on infants' responses to routine vaccinations.
  • The study found that infants born to women who received Tdap vaccination during pregnancy had significantly lower levels of IgG antibodies against pertussis toxin, filamentous haemagglutinin (FHA), pertactin, and fimbria 2/3 after primary immunization compared with those born to unvaccinated women.
  • These lower antibody levels persisted even after booster shots were given for FHA and FIM2/3 in the group whose mothers were vaccinated with Tdap during pregnancy.
  • Infants from this same group also showed lower seroprotection rates against diphtheria following their primary vaccination but higher short-term as well as long-term seroprotection rates against Haemophilus influenzae type b when compared with counterparts from non-vaccinated mothers.
  • Despite these findings suggesting a potential impact on infant immune response due to maternal Tdap vaccination during pregnancy, it's important that post-booster shot seroprotection rates remained high at 99% for both diphtheria and tetanus among all groups studied regardless of maternal status regarding receipt or non-receipt of the Tdap vaccine while pregnant.

Product Monograph / Prescribing Information

Systematic Reviews / Meta-Analyses